Episodes

  • (PART 2) Acne in Paris: Croissants, Comedones & Cutting-Edge Care at EADV 2025

    (PART 2) Acne in Paris: Croissants, Comedones & Cutting-Edge Care at EADV 2025
    Oct 8 2025
    Acne in Paris: Croissants, Comedones & Cutting-Edge Care at EADV 2025Guests: Dr. Chloe Ward & Dr. Natalie CunninghamLocation: 📍 EADV 2025, Paris 🇫🇷From café chatter to late-breaker abstracts, this fresh field report stitches together breaking new data and what matters for acne care today. Our two Canadian derm Faculty dynamos, Dr. Chloe Ward and Dr. Natalie Cunningham, join us live from EADV 2025 to decode acne in the TikTok age. We swap “Dr. Google” for real talk on psychosocial fallout (filters, FOMO, and 4 a.m. routines), sanity-check the diet myths, and map where AI actually helps in assessment—think consistent severity tracking and smarter primary-care triage—without replacing clinical eyes (especially in richer skin tones).Drs. Ward and Cunningham unpack multimodal regimens patients can actually tolerate, topical androgen-receptor blockade at the sebaceous unit, and smarter maintenance so scars don’t steal the show. We dig into pigment beyond classic PIH (hello, primary melanogenesis), when energy devices earn a seat (including a 1726-nm sebaceous-targeting laser), why most at-home red light is a detour, and the rare moments biologics enter the chat for overlap/refractory cases. Throughout: practical pearls and fresh evidence Learning ObjectivesAfter this episode, participants will be able to:🧠 Assess psychosocial burden in acne (sleep 💤, stress 😰, social media behaviors 📱) and integrate into severity and treatment decisions 🩺.🥗 Debunk prevalent myths (“diet cures acne” ❌) with balanced, evidence-based counseling 📖 that acknowledges diet/stress/hormones as contributors, not sole causes ⚖️.🧴 Design patient-centered, multimodal regimens that optimize efficacy ✅ and tolerability 🤝—leveraging combination therapy 🔗.🧬 Explain mechanisms (incl. topical androgen-receptor blockade at the sebaceous gland) and position them in stepwise care from induction 🚀 to maintenance 🔁.🎨 Differentiate pigment pathways (PIH vs. emerging primary melanogenesis) and tailor strategies for all skin tones 🌈 with rigorous photoprotection 🧢🕶️.🤖 Use AI judiciously for documentation 📝 and triage 🏥; recognize limitations in diverse skin tones 🌍 and keep the patient’s lived experience central ❤️.🛡️ Prevent scars proactively by identifying scar-risk patients early ⏱️ and escalating appropriately (e.g., isotretinoin candidacy) 🎯.🔦 Outline the role of energy-based devices (including the 1726-nm sebaceous-targeting laser) in reducing inflammation 🔥, erythema 🌺, and remodeling 🧱—and why most at-home red-light devices fall short 🚫🔴.🧬 Spot the edge cases where biologics or overlap-syndrome thinking may be appropriate 🧩, and outline key research gaps to watch 🔭 (hormonal pathways, AI validation, long-term maintenance). Perfect forDermatologists, primary-care clinicians, pharmacists, nurses, and any HCP who fields “I saw this on TikTok…” and wants practical, patient-first to translate Paris-level science into Monday-morning care. ABOUT Dr Natalie Cunningham, MD FRCPC HALIFAX, NSDr. Cunningham is a co-founder of Maritime Dermatology and was born and raised in Halifax, Nova Scotia. Her roots are in Yarmouth, Nova Scotia and Vienna, Austria. She completed a Bachelor of Science in Neuroscience, Medical School and Dermatology Residency, serving as chief resident, at Dalhousie University. She passed her Royal College examination in 2017. She has been active in medical education and is assistant professor in the department of medicine at Dalhousie medical school. She sees patients of all ages and has a pediatric dermatology clinic at the IWK where she also supervises medical students and residents. She is active in research and has publications in high impact scientific journals and is the research director at Maritime Dermatology. ABOUT Dr. Chloé Ward, MD, FRCP(C), DABD OTTAWA, ONChloé Ward, MD, FRCP(C), DABD is a board-certified dermatologist working alongside our team of plastic surgeons at The Ottawa Clinic. She specializes in cutaneous laser surgery and helps patients with a wide range of cosmetic and medical skin care needs. ABOUT Dr Natalie Cunningham, MD FRCPC HALIFAX, NSDr. Cunningham is a co-founder of Maritime Dermatology and was born and raised in Halifax, Nova Scotia. Her roots are in Yarmouth, Nova Scotia and Vienna, Austria. She completed a Bachelor of Science in Neuroscience, Medical School and Dermatology Residency, serving as chief resident, at Dalhousie University. She passed her Royal College examination in 2017. She has been active in medical education and is assistant professor in the department of medicine at Dalhousie medical school. She sees patients of all ages and has a pediatric dermatology clinic at the IWK where she also supervises medical students and residents. She is active in research and has publications in high impact ...
    Show More Show Less
    23 mins
  • Acne in Paris: Croissants, Comedones & Cutting-Edge Care at EADV 2025

    Acne in Paris: Croissants, Comedones & Cutting-Edge Care at EADV 2025
    Oct 6 2025
    Acne in Paris: Croissants, Comedones & Cutting-Edge Care at EADV 2025Guests: Dr. Chloe Ward & Dr. Natalie CunninghamLocation: 📍 EADV 2025, Paris 🇫🇷From café chatter to late-breaker abstracts, this fresh field report stitches together breaking new data and what matters for acne care today. Our two Canadian derm Faculty dynamos, Dr. Chloe Ward and Dr. Natalie Cunningham, join us live from EADV 2025 to decode acne in the TikTok age. We swap “Dr. Google” for real talk on psychosocial fallout (filters, FOMO, and 4 a.m. routines), sanity-check the diet myths, and map where AI actually helps in assessment—think consistent severity tracking and smarter primary-care triage—without replacing clinical eyes (especially in richer skin tones).Drs. Ward and Cunningham unpack multimodal regimens patients can actually tolerate, topical androgen-receptor blockade at the sebaceous unit, and smarter maintenance so scars don’t steal the show. We dig into pigment beyond classic PIH (hello, primary melanogenesis), when energy devices earn a seat (including a 1726-nm sebaceous-targeting laser), why most at-home red light is a detour, and the rare moments biologics enter the chat for overlap/refractory cases. Throughout: practical pearls and fresh evidence Learning ObjectivesAfter this episode, participants will be able to:🧠 Assess psychosocial burden in acne (sleep 💤, stress 😰, social media behaviors 📱) and integrate into severity and treatment decisions 🩺.🥗 Debunk prevalent myths (“diet cures acne” ❌) with balanced, evidence-based counseling 📖 that acknowledges diet/stress/hormones as contributors, not sole causes ⚖️.🧴 Design patient-centered, multimodal regimens that optimize efficacy ✅ and tolerability 🤝—leveraging combination therapy 🔗.🧬 Explain mechanisms (incl. topical androgen-receptor blockade at the sebaceous gland) and position them in stepwise care from induction 🚀 to maintenance 🔁.🎨 Differentiate pigment pathways (PIH vs. emerging primary melanogenesis) and tailor strategies for all skin tones 🌈 with rigorous photoprotection 🧢🕶️.🤖 Use AI judiciously for documentation 📝 and triage 🏥; recognize limitations in diverse skin tones 🌍 and keep the patient’s lived experience central ❤️.🛡️ Prevent scars proactively by identifying scar-risk patients early ⏱️ and escalating appropriately (e.g., isotretinoin candidacy) 🎯.🔦 Outline the role of energy-based devices (including the 1726-nm sebaceous-targeting laser) in reducing inflammation 🔥, erythema 🌺, and remodeling 🧱—and why most at-home red-light devices fall short 🚫🔴.🧬 Spot the edge cases where biologics or overlap-syndrome thinking may be appropriate 🧩, and outline key research gaps to watch 🔭 (hormonal pathways, AI validation, long-term maintenance). Perfect forDermatologists, primary-care clinicians, pharmacists, nurses, and any HCP who fields “I saw this on TikTok…” and wants practical, patient-first to translate Paris-level science into Monday-morning care. ABOUT Dr Natalie Cunningham, MD FRCPC HALIFAX, NSDr. Cunningham is a co-founder of Maritime Dermatology and was born and raised in Halifax, Nova Scotia. Her roots are in Yarmouth, Nova Scotia and Vienna, Austria. She completed a Bachelor of Science in Neuroscience, Medical School and Dermatology Residency, serving as chief resident, at Dalhousie University. She passed her Royal College examination in 2017. She has been active in medical education and is assistant professor in the department of medicine at Dalhousie medical school. She sees patients of all ages and has a pediatric dermatology clinic at the IWK where she also supervises medical students and residents. She is active in research and has publications in high impact scientific journals and is the research director at Maritime Dermatology. ABOUT Dr. Chloé Ward, MD, FRCP(C), DABD OTTAWA, ONChloé Ward, MD, FRCP(C), DABD is a board-certified dermatologist working alongside our team of plastic surgeons at The Ottawa Clinic. She specializes in cutaneous laser surgery and helps patients with a wide range of cosmetic and medical skin care needs. ABOUT Dr Natalie Cunningham, MD FRCPC HALIFAX, NSDr. Cunningham is a co-founder of Maritime Dermatology and was born and raised in Halifax, Nova Scotia. Her roots are in Yarmouth, Nova Scotia and Vienna, Austria. She completed a Bachelor of Science in Neuroscience, Medical School and Dermatology Residency, serving as chief resident, at Dalhousie University. She passed her Royal College examination in 2017. She has been active in medical education and is assistant professor in the department of medicine at Dalhousie medical school. She sees patients of all ages and has a pediatric dermatology clinic at the IWK where she also supervises medical students and residents. She is active in research and has publications in high impact ...
    Show More Show Less
    20 mins
  • Melinda Knows Best: EADV 2025 Chronic Hand Eczema Paris Pop-Up with Dr.Melinda Gooderham

    Melinda Knows Best: EADV 2025 Chronic Hand Eczema Paris Pop-Up with Dr.Melinda Gooderham
    Oct 2 2025
    Paris Pop-Up: Hands Down the Most Fun You’ll Have Learning About Chronic Hand Eczema Late Breaker EditionChronic Hand Eczema in Focus: DELTA-Teen efficacy & pooled safety of topical pan-JAK Episode Tasting Menu 🍽️:Jet-lag ✈️, steak-frites , and NEW science : we unpack fresh adolescent data for a topical pan-JAK cream in chronic hand eczema (CHE) and a pooled safety package that’s so uneventful it’s…beautiful 😌. (Melinda’s words: “Boring is good.”)Fresh from EADV Paris 🗼🇫🇷, the team breaks down two late-breaking updates on CHE:DELTA-Teen — a randomized (3:1) 16-week trial of a topical pan-JAK inhibitor (delgocitinib cream) in adolescents (12–17) with moderate–severe CHE. 📊Pooled safety analysis across five trials (Phase 2b/3; 16-week regular use + up to 52-week as-needed). 🛡️📈What’s on the tasting menu :• EADV in Paris — highlights with a dash of Melinda’s Paris story 🥐📸• Current adolescent CHE care — steroid limits & non-steroidal gaps • DELTA-Teen unpacked — design, endpoints, results, onset, adherence impact • Safety deep-dive — pooled 5-trial analysis, 52-week PRN, counseling talking points • Practice pearls — payer metrics (IGA-CHE), cross-setting messaging, fast-tracking from primary care • Wrap — off-label nuance, what to tell parents/teens, what to watch for nextWe dive into where a non-steroidal topical JAK can fit for adolescents—an area with gaps given steroid hesitancy and tolerability issues with other non-steroidals 🧩.Plus, a practical workflow map 🗺️: primary care triage → dermatology fast-track → pharmacy counseling (steroid fears, adherence benefits from rapid itch relief) → documentation (expect IGA-CHE to be required by payers). Importantly, efficacy signals span CHE subtypes (atopic, irritant, allergic) ✅—supporting broad real-world relevance 🌍. Learning objectives 🎯:Describe the DELTA-Teen trial design for adolescent CHE, including primary (IGA-CHE TS) and key secondary endpoints (HECSI-90, HESD itch/pain).Interpret week-16 efficacy results and differentiate early patient-reported benefits from statistical-significance timing (e.g., week-12 separation)—and weave this into adherence counseling ⏳.Summarize pooled safety across five trials (16-week regular use + up to 52-week PRN): common AEs, no increased AE rates vs vehicle, and implications of minimal systemic absorption & no boxed warning for topical delgocitinib 🛡️📉.Identify gaps in adolescent CHE management (steroid limitations, tolerability of other non-steroidals) and position topical pan-JAK inhibitors appropriately—acknowledging off-label use where applicable 🧭.Apply a care-pathway playbook (primary care → dermatology → pharmacy counseling → payer documentation) and document outcomes likely required for access (e.g., IGA-CHE scoring) across CHE subtypes 📋✅. Practical pearls (AKA Clinic Cheat Codes) :• Expect early itch relief that can boost adherence; set expectations about week-12 statistical separation ⏱️🙌.• Use IGA-CHE in documentation; keep HECSI-90/HESD in mind for research/quality initiatives 📝🔍.• Safety talking points: AEs comparable to vehicle; long-term PRN data up to 52 weeks; discuss the no boxed warning context vs class concerns 🛡️🗣️.• Reinforce steroid-sparing options to address teen/parent anxieties about skin thinning 🧴.• Subtype-agnostic efficacy supports practical use while you sort mixed etiologies 🧪🔄.—Notes ⚠️🗒️: Adolescent use discussed here reflects off-label prescribing in many regions pending any label extension. Always consult local product labeling and guidance.#SkinAndJointsPodcast #ChronicHandEczema #CHE #EADV2025 #Paris #Dermatology #DELTATeen #Delgocitinib #JAKInhibitor #TopicalJAK #AdolescentDerm #PediatricDerm #ItchRelief #SteroidSparing #ClinicalTrials #RealWorldEvidence #IGACHE #HECSI90 #HESD #PracticePearls #DermPharmacy #MedEd #HCPs #EvidenceBasedDermSUPPORTED BY AN IME GRANT FROM LEO PHARMA ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)Toronto, ONMelinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.📻www.skinandjoints.ca✉️info@skinandjoints.ca 📻www.skinandjoints.ca✉️info@skinandjoints.ca Hosted ...
    Show More Show Less
    25 mins
  • To Switch or Not to Switch? With Dr. Jensen Yeung and Dr. Ron Vender

    To Switch or Not to Switch? With Dr. Jensen Yeung and Dr. Ron Vender
    May 28 2025
    🎙️ Our PsO Playbook: Brothers on the Fairway, Biologics Experts in the Clinic ⛳️🧬✨What happens when two Ontario derms swap the golf course for the Skin and Joints studio? You get a rapid-fire, real-world deep dive into bimekizumab for plaque psoriasis—complete with candid golf confessions, myth-busting on intra-class switching, and a candidiasis reality check you can actually use.Dr. Ron Vender (80 rounds a season 🙌) and Dr. Jensen Yeung (proud caddy and data devotee) unpack their 16-week, multicentre retrospective review of adults with moderate to severe PsO who’d already tangoed with other IL-17 inhibitors. Spoiler: 86 % hit IGA 0/1 and PASI 90, while 63 % nailed PASI 100. Not bad for so-called “tough” patients.Expect quick-hit pearls on why dual IL-17 A + F blockade matters, how to frame the switch and treatment class conversation in 30 seconds, and why starting with your heaviest hitter first-line might be a good real world strategy️‍♀️💡🎯 Learning ObjectivesDecode the Data 📊Translate 16-week real-world outcomes (IGA 0/1, PASI 90/100) into day-to-day decision-making for IL-17–experienced psoriasis patients.Master the Switch 🔄Compare primary vs secondary non-responders—and justify when intra-class IL-17 switching still makes clinical (and payer) sense.Counsel with Confidence 🗣️Craft a 30-60-second convo to prep patients to set realistic skin clearance expectations.Rethink the Ladder 🪜Debate first-line versus “last-resort” positioning the current IL-17 vs IL-23 landscape.Plan for Durability 📅Identify unanswered questions—1-year persistence, multi-failure cohorts—and how ongoing real-world follow-up could reshape treatment algorithms.🔔 Hit play, level up your treatment playbook, and maybe even shave a few strokes off your psoriasis management game. #SkinAndJointsPodcast #PsoriasisPearls 🩺EXCLUSIVE TO THE SKIN AND JOINTS PODCAST About Dr. Ron Vender MD, FRCPCDermatologist | HamiltonDr. Ron Vender is a Dermatologist who currently practices in Hamilton. He is the founder and director of Dermatrials Research Incorporated and Venderm Innovations in Psoriasis. He has participated as principal investigator in over 100 clinical trials. He is Associate Clinical Professor at McMaster University in the Department of Medicine, Division of Dermatology. Dr. Vender serves on the editorial board of the Journal of Cutaneous Medicine and Surgery reviewer for the JEADV, JAAD, and BJD. He is one of eight Canadians elected to the International Psoriasis Council, a member of the Canadian Professors of Dermatology and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis. He represents Canada on several global educational steering committees as well as international advisory boards. He has published over 100 peer-reviewed manuscripts and has had posters, abstracts and lectures presented internationally. About Dr.Jensen Yeung MD, FRCPCDermatologist | Toronto Dr. Jensen Yeung obtained a B.Sc. (Honours) and MD from McMaster University in 2001. In the same year, he began his dermatology residency training at the University of Toronto. During his residency training, he spent 6 months in Australia, New York, and Boston gaining clinical experience and acquiring the newest knowledge in the field of melanoma and dermoscopy from leading experts. In 2005, he was selected by the residency program as the co-chief resident for the year. Having obtained his board certification from the Royal College of Physicians and Surgeons of Canada in 2006, he joined the Faculty of Dermatology at the University of Toronto, where he ran teaching clinics at both Women’s College Hospital and the Sunnybrook Health Sciences Centre. In 2007, he was promoted to the position of medical director for the RKS Dermatology Program at Women’s College Hospital, where he ran a melanoma, psoriasis, and General Dermatology clinic. In 2013, he switched from RKS to PERC and took on the new role as the medical director of PERC (phototherapy education and research centre) where he runs weekly psoriasis/phototherapy clinic. In 2014, he and Dr. Dana Jerome started a monthly combined psoriasis/psoriatic arthritis clinic at PERC. In 2011, he joined Dr. Kim Papp’s research facility in Waterloo and has participated in over 200 phase 1 to 4 clinical trials. He has also supervised and mentored many research students and residents, which has led to around 180 peer-reviewed publications. He is an associate editor at JCMS and Canadian Dermatology Today. He has received a number of teaching awards including the best resident teacher award in 2005, the 2008 Women’s College Hospital Department of Medicine Postgraduate Teaching Award, the 2009 University of Toronto Dermatology Postgraduate Program Staff Teaching Award, and the 2023 University of Toronto Department of Medicine Award for Excellence in Postgraduate Teaching.📻www.skinandjoints.ca✉️info@...
    Show More Show Less
    33 mins
  • Navigating the Pharmacy Acne Aisle with Dr. Sonya Abdulla: Ingredient Deepdive PART 3

    Navigating the Pharmacy Acne Aisle with Dr. Sonya Abdulla: Ingredient Deepdive PART 3
    May 20 2025

    🎙️ Before the Referral to Dr. Abdulla: Filling Your Acne 🛒 ‘Shopping Cart’—Rapid-Fire Ingredients & Real-World Care Considerations (Part 3 of 3)

    Episode description

    While your patient sits on a six-month wait-list for dermatology, their acne isn’t taking a holiday.

    In the finale of our ingredient deep-dive mini-series, Dr. Sonya Abdulla add to the bulging cart: neo-glucosamine 🧴, glycerin 💧, niacinamide ✨, probiotics 🦠, peptides 🧬, and the aisle heroes—salicylic acid, benzoyl peroxide, and retiinol

    Dr. Abdulla also tackles a practice gap too many overlook: the act of referral is not a management plan.

    Tune in for bite-sized, practical scripts for product layering ➡️🧖‍♀️➡️🌞 and a myth-busting look at the microbiome 🤯

    Powered by a rapid-fire Q&A, and (yes) a self-checkout beep 🔊, this episode hands you an expert toolkit 🧰 to keep acne care moving—because ⏱️ timing is everything.

    Learning objectives

    ⏩ – Identify two evidence-based prescription or OTC therapies to start while patients await referral.

    🧪 – Compare how neo-glucosamine, glycerin, niacinamide, salicylic acid, benzoyl peroxide & retinol hit the four pillars of acne pathophysiology.

    🔍 – Summarize current evidence (and limits) for probiotics & peptides in acne care, guiding realistic patient expectations.

    🤝 – List practical tips and resources that keep pharmacists, GPs & dermatologists co-aligned along the acne journey.


    #SkinAndJointsPodcast #AcneCare #DermTips #PrimaryCare #PharmacyPearls #SkinBarrier #IngredientDeepDive #StartLowGoSlow #DermEducation #Neutrogena #AcneAisleMiniSeries #SkinAndJointsPodcast #PharmToDerm 🛍️💡

    Made possible with the support of Kenvue Neutrogena

    Opinions are for educational purposes only and do not replace individualized medical advice.

    ABOUT Dr. Sonya Abdulla

    Dermatologist, TORONTO, ON

    Dr. Abdulla is a board-certified dermatologist in Canada and the USA and has a blended medical and aesthetic dermatology practice at Dermatology on Bloor in Toronto. She earned her degree from the University of Ottawa, where she was awarded the Dr. André Peloquin Award for excellence in patient care. She completed additional Fellowship training in Dermatologic Laser Surgery and Aesthetic Medicine at the University of Toronto.

    Dr. Abdulla is an active member of the Canadian Dermatology Association, American Academy of Dermatology, American Society of Dermatologic Surgery, European Academy of Dermatology and Venereology, Ontario Medical Association, and Canadian Medical Association. Additionally, she is a published author with numerous articles in peer-reviewed scientific journals.

    📻www.skinandjoints.ca

    ✉️info@skinandjoints.ca


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Show More Show Less
    19 mins
  • Navigating the Pharmacy Acne Aisle with Dr. Sonya Abdulla: Ingredient Deepdive PART 2

    Navigating the Pharmacy Acne Aisle with Dr. Sonya Abdulla: Ingredient Deepdive PART 2
    May 13 2025

    🎙️ Skin & Joints Podcast — Acne Aisle Adventure with Dr. Sonya Abdulla (Part 2 of 3) 🎙️

    Dr. Sonya Abdulla is back at the mic, and her shopping cart is starting to look like it needs four-wheel drive. This second instalment rockets from benzoyl-peroxide to sulfur’s glow-up (no more rotten-egg vibes), detours into niacinamide’s barrier-boosting superpowers, and lands on why retinol deserves a nightly standing ovation. 🛒💥🧴

    Learning Objectives 📚✨

    By the end of Part 2, listeners will be able to:

    1. Dose & Dispense Like a Pro
    2. Spot-Treat Smarter
    3. Master the Mixology
    4. Escalate with Confidence

    🔍 Ingredient Sneak Peek — What’s Rolling onto the Conveyor Belt:

    • Benzoyl Peroxide: The OG bacteria-slayer
    • Sulfur: Acne care’s retro revival
    • Niacinamide: The Swiss-army vitamin
    • Retinol / Retinaldehyde: Night-shift gene whisperers that keep new breakouts from ever RSVPing.
    • Hydrocolloid Patches: Tiny panic rooms for pimples

    Catch the full low-down (percentages, pro hacks, and combo tricks) in the episode—your shopping cart will never be the same. 🎧🛒💥

    #AcneAisleMiniSeries #SkinAndJointsPodcast #PharmToDerm 🛍️💡

    Made possible with the support of Kenvue Neutrogena

    ABOUT Dr. Sonya Abdulla

    Dr. Abdulla is a board-certified dermatologist in Canada and the USA and has a blended medical and aesthetic dermatology practice at Dermatology on Bloor in Toronto. She earned her degree from the University of Ottawa, where she was awarded the Dr. André Peloquin Award for excellence in patient care. She completed additional Fellowship training in Dermatologic Laser Surgery and Aesthetic Medicine at the University of Toronto.

    Dr. Abdulla is an active member of the Canadian Dermatology Association, American Academy of Dermatology, American Society of Dermatologic Surgery, European Academy of Dermatology and Venereology, Ontario Medical Association, and Canadian Medical Association. Additionally, she is a published author with numerous articles in peer-reviewed scientific journals.

    Made possible with the support of Kenvue Neutrogena

    📻www.skinandjoints.ca

    ✉️info@skinandjoints.ca
    Show More Show Less
    20 mins
  • Navigating the Pharmacy Acne Aisle with Dr. Sonya Abdulla: Ingredient Deepdive PART 1

    Navigating the Pharmacy Acne Aisle with Dr. Sonya Abdulla: Ingredient Deepdive PART 1
    Apr 29 2025

    🛒 Skin & Joints Podcast — Acne Aisle Adventure (Part 1 of 3) 🛒
    Ready to turn the drug‑store shelf into your acne‑fighting playground? In this episode host‑with‑the‑most Erin Sahota tags in Toronto derm dynamo Dr. Sonia Abdulla for a cart‑cramming romp through OTC land. From prairie roots to downtown Toronto chic, Dr. A spills secrets on why salicylic acid is the Beyoncé of beta‑hydroxy acids, how to stop patients from “more‑is‑more” exfoliation crimes, and where pharmacists now fit in the prescription‑plus‑product relay race. Expect real‑talk on field therapy vs. spot shots, evidence‑based label sleuthing, and the brand‑new “Dr. Abdulla’s Shopping Cart” lightning round—because nothing says skin‑science like a checkout beep. 🎧✨

    Learning Objectives

    By the end of Part 1, listeners will be able to:

    Decode the Acne Aisle: List the must‑know OTC actives (salicylic acid, benzoyl peroxide, retinoids, azelaic acid) and match them to cleanser, leave‑on, and spot‑treatment roles.

    Coach Like a Pro: Craft patient counseling that sets realistic timelines (2–12 weeks), emphasizes whole‑field application, and prevents over‑zealous scrubbing sabotage.

    Sync the Derm‑Pharm Duo: Describe how expanded pharmacist prescribing for mild acne can bridge access gaps and how consistent messaging keeps patients on track.

    Build a Tiered Toolkit: Assemble product “menus” at multiple price points—because evidence‑based care shouldn’t hinge on a wallet size.

    Grab your earbuds, your metaphorical basket, and part‑two‑worthy curiosity—the checkout line is just getting started! #SkinAndJointsPodcast #AcneUnlocked #PharmToDerm 🛒🧴💥

    ABOUT Dr. Sonya Abdulla

    Dr. Abdulla is a board-certified dermatologist in Canada and the USA and has a blended medical and aesthetic dermatology practice at Dermatology on Bloor in Toronto. She earned her degree from the University of Ottawa, where she was awarded the Dr. André Peloquin Award for excellence in patient care. She completed additional Fellowship training in Dermatologic Laser Surgery and Aesthetic Medicine at the University of Toronto.

    Dr. Abdulla is an active member of the Canadian Dermatology Association, American Academy of Dermatology, American Society of Dermatologic Surgery, European Academy of Dermatology and Venereology, Ontario Medical Association, and Canadian Medical Association. Additionally, she is a published author with numerous articles in peer-reviewed scientific journals.

    Made possible with the support of Kenvue Neutrogena

    📻www.skinandjoints.ca

    ✉️info@skinandjoints.ca
    Show More Show Less
    20 mins
  • PART 2: What's New in Atopic Dermatitis at AAD 2025 with Dr. Wei Jing Loo

    PART 2: What's New in Atopic Dermatitis at AAD 2025 with Dr. Wei Jing Loo
    Apr 10 2025

    🎙️ Part 2 – Safety First 🛡️✨

    Still basking in Orlando sun, the crew zooms from efficacy fireworks to the serious stuff: a massive 2,500-patient-year integrated safety update on abrocitinib. Dr. Loo runs the numbers so you don’t have to:

    • Four-and-a-half years of data, ~1,600 patients, ages 18–39 📊
    • No signal for VTE, MACE, or new malignancies despite the boxed-warning hype 🚫❤️‍🩹
    • Main watch-out: shingles (herpes zoster) pops more in adults than teens

    Dr. Liu’s playbook:

    • Benefit → then risk. The speedy itch-relief first, mention nausea/headache next, finish with Black-Box context (RA ≠ AD, pan vs selective JAK).
    • Vaccinate, don’t vacillate. Shingrix before, during, or after start—flexibility wins.
    • Lab light-touch. CBC, LFTs, creatinine at baseline & month 1, then q6mo.
    • Dose dance. 200 mg for “put-out-the-fire” severe cases; 100 mg for teens, 65+ or comorbidity-heavy adults—with room to escalate.

    🎯 Learning Objectives
    • Summarize long-term safety signals of abrocitinib in moderate–severe AD and contrast them with boxed-warning concerns.
    • Apply age- and risk-stratified dosing in shared decision-making for JAK initiation or escalation.

    #SkinAndJointsPodcast #AAD2025 #JAKSafety #Abrocitinib #EczemaCare #DermEd #ItchRelief #MedTwitter 🎧

    About Dr Wei Jing Loo, BSc (Med), MBBS, MRCP (UK), FRCP(c)

    Dermatologist | London, ON

    Dr Wei Jing Loo is the owner and Medical Director of DermEffects, a cutting edge dermatology centre located in London, Ontario. Dr Loo completed medical school in 1997 with an honours degree from the University of New South Wales in Sydney, Australia. She trained in Internal Medicine and obtained membership in the Royal College of Physicians in the United Kingdom in 1999. She completed her dermatology residency training in Cambridge, United Kingdom and obtained her Certificate of Specialist Training in Dermatology in 2005. She is board certified in Canada and a fellow of the Royal College of Physicians and Surgeons of Canada. She is a member of the Canadian Dermatology Association and American Academy of Dermatology.

    Dr. Loo is at the forefront of the dynamic field of dermatology, serving as an associate investigator for Probity Medical Research. Dr. Loo is an Adjunct Professor at Western University in Ontario. She enjoys teaching and has published her work in many peer-reviewed journals

    📻www.skinandjoints.ca

    ✉️info@skinandjoints.ca


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Show More Show Less
    21 mins